Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Gibbs

Orthopaedic Trauma Fleming Island, FL Medical Doctor

NPI 1093125676 CMS profile 4221316

4689 Highway 17, Suite 11, Fleming Island, FL 32003

Open in the dashboard

General payments

$11,096

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Gibbs of Fleming Island, FL is reported in the CMS Open Payments database as having received $11,096 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,671 30
2024 General $1,196 32
2023 General $1,587 35
2022 General $2,835 44
2021 General $442 14
2020 General $1,539 9
2019 General $826 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Gibbs
  • Orthopaedic Trauma median
  • Middle half of Orthopaedic Trauma
  • National median

In program year 2025, general payments to Stephen Gibbs were reported at $2,671. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.

Show as a table
Year Stephen Gibbs Orthopaedic Trauma median Middle half National median
2019 $826 $1,475 $264–$6,401 $163
2020 $1,539 $596 $120–$4,020 $114
2021 $442 $919 $171–$4,697 $132
2022 $2,835 $1,547 $272–$7,240 $149
2023 $1,587 $1,330 $247–$5,875 $160
2024 $1,196 $1,288 $277–$6,797 $164
2025 $2,671 $1,227 $259–$7,433 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $5,952 97 payments
  2. Acumed LLC $2,433 12 payments
  3. Synthes GmbH $1,106 2 payments
  4. DePuy Synthes Sales Inc. $698 44 payments
  5. Smith+Nephew, Inc. $182 2 payments
  6. Integra LifeSciences Corporation $181 6 payments
  7. Next Science LLC $164 2 payments
  8. Medtronic USA, Inc. $111 1 payment
  9. Trilliant Surgical LLC. $80 1 payment
  10. Medinc of Texas $42 1 payment
  11. Other $147 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,688 159 payments
  2. Travel and Lodging $3,990 11 payments
  3. Grant $250 1 payment
  4. Education $168 3 payments
Products named General payments · program years 2019–2025
  1. MAKO $1,177 12 payments
  2. T2 $1,032 15 payments
  3. HOFFMANN $880 14 payments
  4. GAMMA $872 13 payments
  5. VARIAX $792 17 payments
  6. ACUMED Hand & Wrist $738 2 payments
  7. ACUMED Foot & Ankle $729 5 payments
  8. PRO $601 5 payments
  9. ACUMED Hip & Pelvis $584 3 payments
  10. AXSOS $281 5 payments
  11. Other $6,012 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

25

Median for Orthopedic Surgery: 203

Drug cost

$88

Median for Orthopedic Surgery: $1,433

Branded share of claims

56%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 14 $70
Tramadol Hcl Generic 11 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$70,958

Medicare's payments for the services billed

Medicare patients

116

Average age 78

Services billed

311

83 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 52%
Diabetes 47%
Heart failure 37%
Depression 37%
Chronic kidney disease 36%
COPD 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Trauma in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record